INOZYME PHARMA INC (INZY) Stock Earnings & Estimates
NASDAQ:INZY - US45790W1080 - Common Stock
4 USD
+0.01 (+0.25%)
3.99 USD
-0.01 (-0.25%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 3,284.07% | N/A 229.59% | N/A 59.16% | N/A 73.86% | N/A 42.12% | N/A 32.68% | ||||||||
| EBITDA YoY % growth | -11.56M | -20.73M -79.33% | -56.82M -174.10% | -55.98M 1.48% | -67.94M -21.36% | -74.812M -10.11% | -103.288M -38.06% | N/A 6.70% | N/A -23.62% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -11.59M | -20.81M -79.55% | -57.04M -174.10% | -56.65M 0.68% | -68.68M -21.24% | -75.645M -10.14% | -104.03M -37.52% | N/A 0.18% | N/A -15.60% | N/A 8.73% | N/A -0.69% | N/A 45.32% | N/A 186.38% | N/A 307.61% | N/A 53.86% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2.39 49.64% | -1.89 20.92% | -1.37 27.51% | -1.62 -18.25% | N/A 9.62% | N/A 19.94% | N/A 31.80% | N/A 92.34% | N/A 600.00% | N/A 63.33% | N/A 36.73% | N/A 10.45% |
All data in USD
| Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.37 16.48% | -0.34 13.32% | -0.36 12.52% | -0.32 28.14% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | -19.451M 28.74% | -17.228M 29.06% | -32.273M -22.11% | N/A |
| EBIT Q2Q % growth | -24.924M 9.91% | -24.653M 0.80% | -26.843M 1.21% | -29.728M -15.28% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | -0.44 -15.79% | -0.42 | -0.02 | -5.86% |
| Q4 2024 Q2Q % growth | -0.41 -24.24% | -0.41 | 0.00 | 0.94% |
| Q3 2024 Q2Q % growth | -0.39 -34.48% | -0.44 | 0.05 | 12.28% |
| Q2 2024 Q2Q % growth | -0.44 -25.71% | -0.40 | -0.04 | -10.77% |
| Q1 2024 Q2Q % growth | -0.38 5.00% | -0.37 | -0.01 | -3.49% |
| Q4 2023 Q2Q % growth | -0.33 21.43% | -0.32 | -0.01 | -1.56% |
| Q3 2023 Q2Q % growth | -0.29 23.68% | -0.32 | 0.03 | 10.11% |
| Q2 2023 Q2Q % growth | -0.35 7.89% | -0.44 | 0.09 | 20.75% |
| Q1 2023 Q2Q % growth | -0.40 43.66% | -0.45 | 0.05 | 12.07% |
| Q4 2022 Q2Q % growth | -0.42 46.84% | -0.46 | 0.04 | 8.84% |
| Q3 2022 Q2Q % growth | -0.38 36.67% | -0.44 | 0.06 | 14.22% |
| Q2 2022 Q2Q % growth | -0.38 28.30% | -0.49 | 0.11 | 22.15% |
| Q1 2022 Q2Q % growth | -0.71 -51.06% | -0.84 | 0.13 | 15.28% |
| Q4 2021 Q2Q % growth | -0.79 21.78% | -0.70 | -0.09 | -13.07% |
| Q3 2021 Q2Q % growth | -0.60 61.29% | -0.62 | 0.02 | 3.65% |
| Q2 2021 Q2Q % growth | -0.53 93.00% | -0.58 | 0.05 | 8.84% |
| Q1 2021 Q2Q % growth | -0.47 | -0.55 | 0.08 | 14.91% |
| Q4 2020 Q2Q % growth | -1.01 | -0.56 | -0.45 | -81.35% |
| Q3 2020 Q2Q % growth | -1.55 | -0.52 | -1.03 | -197.96% |
| Q2 2020 Q2Q % growth | -7.57 | -1.44 | -6.13 | -425.42% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -0.01% | -3.31% | -3.7% | -4.2% |
| Revenue | N/A | N/A | N/A | N/A |